Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmission of virulent virus

Devlin, Joanne M.; Hartley, Carol A.; Gilkerson, James R.; Coppo, Mauricio J. C.; Vaz, Paola; Noormohammadi, Amir H.; Wells, Ben; Rubite, Ambrosio; Dhand, Navneet K.; Browning, Glenn F.

Abstract

Infectious laryngotracheitis virus (ILTV) is an alphaherpesvirus that causes acute respiratory disease in chickens worldwide. The virus is horizontally transmitted and causes large outbreaks of disease. Recent studies have shown that a glycoprotein G deficient candidate vaccine strain of ILTV (Delta gG ILTV) is safe and protects birds from disease following challenge with virulent virus. This study examined the transmission dynamics of this candidate vaccine and of ILTV in field and experimental settings. The reproduction ratio (R-0, average number of secondary infectious cases from a typical infectious case) was calculated from the growth rate of disease epidemics in broiler flocks. Assuming a latent period of 2 days and an infectious period of 4 days R-0 was estimated to be 2.43(95% CI 2.25-2.69). In experimental settings the transmission characteristics of Delta gG ILTV were similar to those of wildtype virus, and importantly Delta gG ILTV remained safe following one in vivo passage and subsequent infection via contact-exposure. There was minimal transmission of wildtype virus in vaccinated birds. The findings from this study further demonstrate the suitability of Delta gG ILTV for use as a live attenuated vaccine. Knowledge of the basic reproduction ratio of ILTV will be valuable for future studies that aim to improve disease control using vaccination programs. (C) 2011 Elsevier Ltd. All rights reserved.

Más información

Título según WOS: ID WOS:000294145800018 Not found in local WOS DB
Título de la Revista: VACCINE
Volumen: 29
Número: 34
Editorial: ELSEVIER SCI LTD
Fecha de publicación: 2011
Página de inicio: 5699
Página final: 5704
DOI:

10.1016/j.vaccine.2011.06.002

Notas: ISI